LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

A comparative study on schizophyllan and chitin nanoparticles for ellagic acid delivery in treating breast cancer.

Photo by nci from unsplash

In this study, following encapsulation of ellagic acid (EA), an anti-cancer agent, loaded in schizophyllan (EA/SPG-NP) and chitin (EA/Ch-NP) nanoparticles, its release in 95% ethanol, and different mediums of digestive… Click to show full abstract

In this study, following encapsulation of ellagic acid (EA), an anti-cancer agent, loaded in schizophyllan (EA/SPG-NP) and chitin (EA/Ch-NP) nanoparticles, its release in 95% ethanol, and different mediums of digestive systems with pH ranging 1.5 to 7.4, were examined before investigating for treatment of breast cancer MCF-7cells. Following synthesis, the EA was characterized by FT-IR, SEM, XRD, DLS and zeta potential analysis. Loading capacity of schizophyllan and chitin were 30.08 and 79.52%, respectively, while SEM images indicated respective size distributions of 217.8 and 39.82 nm, with the corresponding zeta potentials being +27 and -9.14 mV. As EA was loaded in nanoparticles, antioxidant activity, examined by DPPH method, of the free EA was found to be higher than both EA/SPG-NP and EA/Ch-NP, but lower than the latter at 7.4 pH. Interestingly, scavenging activities for EA and EA/SPG-NP reduced for higher pH. The MTT cytotoxicity indicated that EA/SPG-NP and EA/Ch-NP inhibited effectively cell growth of breast cancer cell lines at IC50 of 60 and 115 μg/mL, respectively.

Keywords: breast cancer; cancer; schizophyllan chitin; chitin nanoparticles; ellagic acid

Journal Title: International journal of biological macromolecules
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.